Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Gary Child

Geriatric Medicine Lehi, UT Doctor of Osteopathy

NPI 1063492304 CMS profile 678616

945 W 3200 N, Lehi, UT 84043

Open in the dashboard

General payments

$2,112

144 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Gary Child of Lehi, UT is reported in the CMS Open Payments database as having received $2,112 across 144 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $28 1
2023 General $217 17
2022 General $370 21
2021 General $405 26
2020 General $255 12
2019 General $837 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Child
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Gary Child were reported at $0. Among 512 Geriatric Medicine profiles paid that year, the median was $120 and the middle half received between $37 and $350.

Show as a table
Year Gary Child Geriatric Medicine median Middle half National median
2019 $837 $96 $28–$339 $163
2020 $255 $99 $28–$262 $114
2021 $405 $94 $27–$318 $132
2022 $370 $103 $34–$338 $149
2023 $217 $109 $39–$320 $160
2024 $28 $125 $36–$371 $164
2025 $0 $120 $37–$350 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Collegium Pharmaceutical, Inc. $476 42 payments
  2. Biodelivery Sciences International, Inc. $217 16 payments
  3. Indivior Inc. $151 3 payments
  4. Teva Pharmaceuticals USA, Inc. $135 12 payments
  5. Pfizer Inc. $115 7 payments
  6. Daiichi Sankyo Inc. $108 18 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $99 4 payments
  8. Relievant Medsystems, Inc. $96 1 payment
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $95 6 payments
  10. AbbVie, Inc. $84 4 payments
  11. Other $536 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,112 144 payments
Products named General payments · program years 2019–2024
  1. XTAMPZA $428 38 payments
  2. BELBUCA $154 11 payments
  3. SUBLOCADE $151 3 payments
  4. NURTEC ODT $146 7 payments
  5. Morphabond ER $108 18 payments
  6. Ajovy $106 10 payments
  7. AIMOVIG $97 6 payments
  8. Intracept $96 1 payment
  9. RELISTOR $95 6 payments
  10. LYRICA $92 6 payments
  11. Other $1,057 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

144 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record